Endocyclic Therapeutics

EndoCyclic Therapeutics is a pioneering biopharmaceutical company at the forefront of developing non-hormonal, precision medicines for women’s health and oncology. Utilizing innovative pH-sensitive peptides, we are committed to the development of a first-in-class investigational therapeutic for endometriosis with the potential to revolutionize endometriosis care as a disease-modifying treatment, aimed at eliminating disease and associated symptoms. EndoCyclic is also advancing an investigational imaging diagnostic agent for endometriosis designed to detect all subtypes of the disease, including small superficial lesions and even the earliest stages of disease progression. Our expanding portfolio further includes therapeutics and diagnostics in fibrosis, oncology (including endometrial and colon cancer), and other women’s health diseases. Endometriosis affects over 10% of women globally and is the leading cause of infertility and disability among women of reproductive age. Despite its prevalence, it remains the most overlooked women’s health issue. At EndoCyclic Therapeutics, our team of world-class physicians, scientists, and pharma/biotech professionals is committed to addressing this gap by discovering new solutions that had the potential to definitively diagnose and treat these conditions. Our pH-sensitive peptides are specifically engineered to respond to the altered pH environments found in tumorous and endometriotic tissues, enabling precise delivery of therapeutics and enhancing diagnostic accuracy. This targeted approach is designed to support effective treatment and imaging, with the potential to minimize side effects and improve patient outcomes. For more information about how we’re driving change in women’s health and oncology, and bringing awareness to these critical issues, please visit our website at